Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 335 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: High Salt Clear all
Recruiting Phase 3 Interventional

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT06958328
View directory record Official record
Conditions
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Tumor Treating Fields Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
332
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Active, not recruiting Phase 2 Interventional

Study of JK07 in Patients With Chronic Heart Failure

NCT06369298
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Interventions
JK07, Placebo
Drug
Lead sponsor
Salubris Biotherapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
51
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

NCT01287793
View directory record Official record
Conditions
Healthy
Interventions
tigecycline, moxifloxacin, 100 mL 0.9% Sodium Chloride intravenous, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Oct 26, 2026, 4:34 AM EDT
Recruiting Phase 2 Interventional

Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony

NCT07217899
View directory record Official record
Conditions
Blood Loss, Surgical, Blood Loss, Postoperative, Uterine Atony
Interventions
Calcium Gluconate, Saline
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Withdrawn Phase 1 Interventional

Pulmozyme for Sjogren's Associated Cough

NCT01357447
View directory record Official record
Conditions
Sjogren's Syndrome, Cough
Interventions
Dornase alfa, Saline
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Racial/Ethnic in Calcium and Sodium Metabolism

NCT05537857
View directory record Official record
Conditions
Healthy
Interventions
High dietary salt
Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

NCT00600483
View directory record Official record
Conditions
Cardiac Surgery, Sternal Wound Infection
Interventions
gentamicin-collagen sponge dipped in saline
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older
Enrollment
1,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
43
States / cities
Birmingham, Alabama • Florence, Alabama • Pasadena, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

NCT02742103
View directory record Official record
Conditions
Acute Myocardial Infarction, Moderate Renal Impairment
Interventions
CSL_112, Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • Huntsville, Alabama • Concord, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT03786783
View directory record Official record
Conditions
Ganglioneuroblastoma, High Risk Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Dexrazoxane, Dinutuximab, Doxorubicin, Etoposide, External Beam Radiation Therapy, Isotretinoin, Melphalan, Sargramostim, Thiotepa, Topotecan, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).

NCT06253923
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Amantadine Hydrochloride, Placebo
Drug
Lead sponsor
SHINKEI Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

NCT00770146
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease
Interventions
Mipomersen sodium, Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
62
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 26, 2026, 4:34 AM EDT
Recruiting Phase 4 Interventional

DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes

NCT06983054
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ertugliflozine, low salt diet, placebo, high salt diet
Drug · Behavioral
Lead sponsor
Amsterdam UMC, location VUmc
Other
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)

NCT01585402
View directory record Official record
Conditions
Arterial Calcification, CD73 Deficiency
Interventions
Etidronate, MRI Scan
Drug · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 26, 2026, 4:34 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease

NCT00257543
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alternative donor bone marrow and cord blood
Procedure
Lead sponsor
Emory University
Other
Eligibility
Up to 16 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Trial of Inactivated West Nile Virus Vaccine

NCT02337868
View directory record Official record
Conditions
West Nile Viral Infection
Interventions
HydroVax-001, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 26, 2026, 4:34 AM EDT
Recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

NCT07192458
View directory record Official record
Conditions
Immunization; Infection|Transplantation Infection|Influenza, Influenza
Interventions
Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Not applicable Interventional

Enhancement of Contrast Opacification for Echocardiographic Imaging of the Right Heart and Shunts

NCT02661529
View directory record Official record
Conditions
Bidirectional Cardiovascular Shunt
Interventions
Transesophageal Echocardiogram (TEE), Transthoracic Echocardiogram (TTE), Saline/Air Mixture, Saline/Blood Mixture
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 105 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19

NCT04583969
View directory record Official record
Conditions
COVID-19
Interventions
Lenzilumab, Placebo, Remdesivir
Biological · Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
53
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 26, 2026, 4:34 AM EDT
Terminated Not applicable Interventional

Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention

NCT02818283
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection, Hypercholesterolemia
Interventions
Soy Pretzel, Wheat Pretzel
Dietary Supplement · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing Product Messages for Colombia

NCT04567004
View directory record Official record
Conditions
Obesity
Interventions
Control, Nutriscore Label, Adapted Peruvian Nutrient Label, Guideline Daily Amount Label
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 64 Years
Enrollment
8,071 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Orally Administered Strontium L-Lactate in Healthy Adults

NCT03761979
View directory record Official record
Conditions
Low Bone Density, Osteopenia, Osteoporosis, Postmenopausal
Interventions
Strontium L-lactate
Dietary Supplement
Lead sponsor
BioLink Life Sciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

NCT02108262
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
CSL112, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
1,267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 3 Interventional Results available

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

NCT00980460
View directory record Official record
Conditions
PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma, PRETEXT IV Hepatoblastoma
Interventions
Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Liver Transplantation, Temsirolimus, Therapeutic Conventional Surgery, Vincristine Sulfate
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
184
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 133 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation

NCT02487797
View directory record Official record
Conditions
Dystocia
Interventions
Oxytocin, Sodium Chloride 0.9%
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 26, 2026, 4:34 AM EDT